GDP-bound form of KRASG12C inhibitors have been approved for the treatment of patients with advanced KRASG12C mutant non-small cell lung cancer (NSCLC), however resistance to these drugs is often observed. Here the authors report that combining a GTP-bound RAS G12C-selective inhibitor with SHP2 inhibition can sensitize lung tumours to immune checkpoint blockade.
- Panayiotis Anastasiou
- Christopher Moore
- Julian Downward
